SRTS Stock Price, Sensus Healthcare Inc Quote, Chart

Market Summary

USD5.94-0.48

Market Closed

-7.48%

SRTS Stock Price

View Fullscreen

SRTS RSI Chart

SRTS Valuation

Market Cap

97.4M

Price/Earnings (Trailing)

20.93

Price/Sales (Trailing)

3.08

EV/EBITDA

14.43

Price/Free Cashflow

-21.13

SRTS Price/Sales (Trailing)

SRTS Profitability

EBT Margin

20.37%

Return on Equity

9.09%

Return on Assets

8.12%

Free Cashflow Yield

-4.73%

SRTS Fundamentals

SRTS Revenue

Revenue (TTM)

31.7M

Rev. Growth (Yr)

212.33%

Rev. Growth (Qtr)

-15.15%

SRTS Earnings

Earnings (TTM)

4.7M

Earnings Growth (Yr)

220.06%

Earnings Growth (Qtr)

-45.99%

Breaking Down SRTS Revenue

Last 7 days

12.3%

Last 30 days

82.8%

Last 90 days

26.1%

Trailing 12 Months

104.1%

How does SRTS drawdown profile look like?

SRTS Financial Health

Current Ratio

9.85

SRTS Investor Care

Buy Backs (1Y)

0.02%

Diluted EPS (TTM)

0.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	31.7M	0	0	0
2023	37.6M	30.1M	24.9M	24.4M
2022	31.4M	35.8M	40.2M	44.5M
2021	11.0M	0	0	27.0M
2020	23.5M	17.2M	13.0M	9.6M
2019	25.9M	27.3M	26.8M	27.3M
2018	22.2M	23.3M	24.8M	26.4M
2017	16.1M	17.5M	19.0M	20.6M
2016	11.4M	12.5M	13.7M	14.8M
2015	0	0	0	10.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sensus Healthcare Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 11, 2024	sardano michael	acquired	-	-	20,000	president and general counsel
Dec 19, 2023	martinez magdalena	sold (taxes)	-1,971	2.66	-741	chief operating officer
Sep 14, 2023	sardano joseph c	bought	28,773	2.8773	10,000	chief executive officer
Aug 28, 2023	sardano michael	bought	2,990	2.99	1,000	president and general counsel
Aug 08, 2023	sardano joseph c	bought	38,574	3.8574	10,000	chief executive officer
Aug 08, 2023	sardano michael	bought	3,777	3.7778	1,000	president and general counsel
Jul 31, 2023	rampolla javier	sold (taxes)	-11,923	3.03	-3,935	chief financial officer
May 11, 2023	heinrich john	bought	28,600	2.86	10,000	-
May 10, 2023	sardano joseph c	bought	23,735	2.995	7,925	chief executive officer
May 09, 2023	o'rear samuel	bought	52,669	2.9987	17,564	-

Which funds bought or sold SRTS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Global Financial Private Client, LLC	unchanged	-	7,150	18,950	0.01%
May 16, 2024	Creekmur Asset Management LLC	reduced	-70.56	-43,689	39,364	0.01%
May 16, 2024	JANE STREET GROUP, LLC	added	3.24	24,638	61,841	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	new	-	90,060	90,060	-%
May 15, 2024	D. E. Shaw & Co., Inc.	reduced	-83.21	-108,072	40,033	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	168,918	168,918	-%
May 15, 2024	Royal Bank of Canada	reduced	-25.63	12,000	75,000	-%
May 15, 2024	Squarepoint Ops LLC	new	-	48,439	48,439	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	1,797	4,742	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-29.78	14,155	122,550	-%

Are Funds Buying or Selling SRTS?

Are funds buying SRTS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SRTS

No. of Funds

Unveiling Sensus Healthcare Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	solot edwin lee	9.36%	1,533,281	SC 13G/A
Feb 10, 2023	solot edwin lee	9.49%	1,554,845	SC 13G/A
Feb 07, 2022	solot edwin lee	6.7%	1,115,109	SC 13G/A
Sep 10, 2021	solot edwin lee	5.0%	831,027	SC 13G

Recent SEC filings of Sensus Healthcare Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 18, 2024	PRE 14A	PRE 14A
Mar 15, 2024	10-K	Annual Report

Peers (Alternatives to Sensus Healthcare Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Sensus Healthcare Inc News

Latest updates

Sensus Healthcare Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-15.1%	10,663	12,567	3,898	4,527	3,414	13,104	9,010	12,080	10,338	6,704	3,070	5,095	1,620	1,183	1,679	8,509	5,841	7,476	5,437	8,081	6,334
Gross Profit	-14.9%	6,662	7,831	1,989	2,619	1,622	8,350	5,874	8,256	7,149	8,856	1,586	3,228	672	640	709	5,458	3,844	4,939	3,316	4,861	4,169
Operating Expenses	67.6%	3,775	2,253	3,884	3,746	4,561	4,179	3,713	3,686	3,219	3,537	2,701	2,972	2,951	3,214	4,346	4,474	4,649	4,894	5,509	4,830	4,592
S&GA Expenses	103.4%	1,270	625	1,290	1,595	2,099	1,576	1,807	1,728	1,218	1,336	1,068	1,349	1,034	1,162	1,791	2,453	2,124	1,995	2,530	2,385	1,972
R&D Expenses	37.0%	926	676	1,083	822	1,098	1,159	746	827	728	1,106	661	844	941	1,148	1,225	950	1,568	1,935	1,966	1,485	1,713
EBITDA Margin	6842.5%	0.18*	0.00*	-0.04*	0.09*	0.22*	0.63*	0.73*	0.76*	0.71*	0.18*	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-243	-381	1.00	1.00	-1.00	1.00	-	2.00	3.00	14.00	-	-	-	-	-	-	58.00
Income Taxes	-48.2%	827	1,596	-125	-502	-802	1,578	450	1,070	648	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-46.6%	3,101	5,806	-1,576	-882	-2,696	4,407	2,279	4,594	16,710	5,318	-1,115	-	-	-	-	-	-	-	-	-	-
EBT Margin	663.1%	0.20*	0.03*	-0.03*	0.10*	0.23*	0.63*	0.72*	0.75*	0.70*	0.15*	-	-	-	-	-	-	-	-	-	-	-
Net Income	-46.0%	2,274	4,210	-1,451	-380	-1,894	2,829	1,829	3,524	16,062	5,318	-1,115	1,018	-1,692	-2,574	-3,587	1,039	-730	112	-2,121	102	-458
Net Income Margin	639.7%	0.15*	0.02*	-0.04*	0.08*	0.17*	0.54*	0.67*	0.70*	0.68*	0.15*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-415.6%	-8,420	2,668	431	713	-6,186	-10,123	3,663	1,851	3,038	-1,818	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	6.6%	57.00	54.00	51.00	52.00	53.00	57.00	55.00	56.00	54.00	32.00	26.00	26.00	26.00	28.00	28.00	30.00	32.00	37.00	36.00	36.00	34.00
Current Assets	8.9%	54.00	50.00	46.00	47.00	49.00	53.00	52.00	51.00	48.00	31.00	24.00	24.00	24.00	25.00	25.00	27.00	30.00	34.00	33.00	33.00	32.00
Cash Equivalents	-36.4%	15.00	23.00	20.00	20.00	19.00	26.00	38.00	34.00	33.00	15.00	16.00	15.00	14.00	15.00	16.00	18.00	12.00	8.00	7.00	11.00	6.00
Inventory	24.1%	15.00	12.00	13.00	10.00	6.00	4.00	2.00	2.00	2.00	2.00	2.00	3.00	4.00	4.00	5.00	5.00	4.00	3.00	2.00	2.00	2.00
Net PPE	36.4%	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	24.6%	6.00	5.00	6.00	6.00	7.00	9.00	8.00	11.00	11.00	6.00	5.00	6.00	6.00	7.00	7.00	8.00	8.00	9.00	9.00	8.00	7.00
Current Liabilities	29.9%	5.00	4.00	5.00	5.00	6.00	8.00	7.00	10.00	10.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	7.00	6.00	5.00
Shareholder's Equity	4.8%	51.00	49.00	45.00	46.00	46.00	48.00	47.00	45.00	42.00	26.00	21.00	20.00	20.00	21.00	20.00	22.00	25.00	28.00	27.00	27.00	27.00
Retained Earnings	33.5%	9.00	7.00	3.00	4.00	4.00	6.00	3.00	2.00	-1.88	-17.94	-23.26	-23.45	-23.18	-22.06	-23.08	-21.39	-18.81	-15.23	-16.26	-15.53	-15.65
Additional Paid-In Capital	0.2%	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	43.00	43.00	43.00	43.00	43.00
Shares Outstanding	0.1%	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	17.00	16.00	16.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	46.00	-	-	-	114	-	-	-	51.00	-	-	-	35.00	-	-	-	63.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-406.9%	-8,187	2,668	442	742	-5,997	-10,113	3,723	1,896	3,082	-1,780	1,253	1,356	-1,115	-360	-2,641	2,133	434	460	-1,624	6,176	-7,117
Share Based Compensation	75.0%	91.00	52.00	67.00	66.00	143	50.00	40.00	40.00	57.00	90.00	206	59.00	60.00	62.00	37.00	131	155	150	158	158	155
Cashflow From Investing	-Infinity%	-233	-	31.00	-29.00	-189	-10.00	-60.00	-45.00	14,956	-38.00	-3.00	250	-80.00	-104	353	3,214	3,567	735	-2,903	-911	-1,817
Cashflow From Financing	100.0%	-	-7.00	-39.00	-	6.00	-1,934	211	-978	273	-54.00	-63.00	-54.00	-60.00	-756	-	970	-3.00	-	-	-81.41	2,702
Buy Backs	-	-	-	-27.00	-	-	-	-	-1,005	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SRTS Income Statement

2024-03-31

Condensed Consolidated Statements of Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 10,663	$ 3,414
Cost of sales	4,001	1,792
Gross profit	6,662	1,622
Operating expenses
Selling and marketing	1,270	2,099
General and administrative	1,579	1,364
Research and development	926	1,098
Total operating expenses	3,775	4,561
Income (loss) from operations	2,887	(2,939)
Other income:
Interest income, net	214	243
Other income, net	214	243
Income (loss) before income tax	3,101	(2,696)
Provision for (benefit from) income taxes	827	(802)
Net income (loss)	$ 2,274	$ (1,894)
Net income (loss) per share – basic (in Dollars per share)	$ 0.14	$ (0.12)
diluted (in Dollars per share)	$ 0.14	$ (0.12)
Weighted average number of shares used in computing net income (loss) per share – basic (in Shares)	16,294,970	16,245,343
diluted (in Shares)	16,318,047	16,245,343

SRTS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 14,728	$ 23,148
Accounts receivable, net	19,625	10,645
Inventories	14,720	11,861
Prepaid inventory	3,671	2,986
Other current assets	1,169	888
Total current assets	53,913	49,528
Property and equipment, net	633	464
Deferred tax asset	1,313	2,140
Operating lease right-of-use asset, net	726	774
Other noncurrent assets	688	804
Total assets	57,273	53,710
Current liabilities
Accounts payable and accrued expenses	3,703	2,793
Product warranties	594	538
Operating lease liability, current portion	191	187
Income tax payable	37	37
Deferred revenue, current portion	948	657
Total current liabilities	5,473	4,212
Operating lease liability	553	596
Deferred revenue, net of current portion	40	60
Total liabilities	6,066	4,868
Commitments and contingencies
Stockholders’ equity
Preferred stock, 5,000,000 shares authorized and none issued and outstanding
Common stock, $0.01 par value – 50,000,000 authorized; 16,925,595 issued and 16,392,671 outstanding at March 31, 2024; 16,907,095 issued and 16,374,171 outstanding at December 31, 2023	169	169
Additional paid-in capital	45,496	45,405
Treasury stock, 532,924 shares at cost, at March 31, 2024 and December 31, 2023	(3,519)	(3,519)
Retained earnings	9,061	6,787
Total stockholders’ equity	51,207	48,842
Total liabilities and stockholders’ equity	$ 57,273	$ 53,710

About Sensus Healthcare Inc

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and TransDermal Infusion system. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body, as well as distributes laser devices. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

CEO	Mr. Joseph C. Sardano
WEBSITE	sensushealthcare.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	42

Sensus Healthcare Inc Frequently Asked Questions

What is the ticker symbol for Sensus Healthcare Inc? What does SRTS stand for in stocks?

SRTS is the stock ticker symbol of Sensus Healthcare Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sensus Healthcare Inc (SRTS)?

As of Fri May 17 2024, market cap of Sensus Healthcare Inc is 97.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRTS stock?

You can check SRTS's fair value in chart for subscribers.

What is the fair value of SRTS stock?

You can check SRTS's fair value in chart for subscribers. The fair value of Sensus Healthcare Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sensus Healthcare Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SRTS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sensus Healthcare Inc a good stock to buy?

The fair value guage provides a quick view whether SRTS is over valued or under valued. Whether Sensus Healthcare Inc is cheap or expensive depends on the assumptions which impact Sensus Healthcare Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRTS.

What is Sensus Healthcare Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SRTS's PE ratio (Price to Earnings) is 20.93 and Price to Sales (PS) ratio is 3.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRTS PE ratio will change depending on the future growth rate expectations of investors.